Wegovy maker Novo Nordisk down 4%, heads for worst day since October
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Source link
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Source link
/cloudfront-us-east-2.images.arcpublishing.com/reuters/2KIDAKSCVJIUZM4J4YV5XD74WY.jpg "Saudi Arabia’s race to attract investment dogged by scepticism")
